JP2010513272A - アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 - Google Patents
アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 Download PDFInfo
- Publication number
- JP2010513272A JP2010513272A JP2009541322A JP2009541322A JP2010513272A JP 2010513272 A JP2010513272 A JP 2010513272A JP 2009541322 A JP2009541322 A JP 2009541322A JP 2009541322 A JP2009541322 A JP 2009541322A JP 2010513272 A JP2010513272 A JP 2010513272A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- group
- halo
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CCC(CC1)CC*1[C@](C)OC(C)C Chemical compound CCC(CC1)CC*1[C@](C)OC(C)C 0.000 description 2
- WKYSETOGOPCGST-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c(cc1)cc(Cl)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c(cc1)cc(Cl)c1[N+]([O-])=O)=O WKYSETOGOPCGST-UHFFFAOYSA-N 0.000 description 1
- ULTPMBFRFOMPCB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1cc(C#N)ncn1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1cc(C#N)ncn1)=O ULTPMBFRFOMPCB-UHFFFAOYSA-N 0.000 description 1
- BOKBFEFITGTLEA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1cc(Cl)ncn1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1cc(Cl)ncn1)=O BOKBFEFITGTLEA-UHFFFAOYSA-N 0.000 description 1
- ITWIYDCRMLYAJX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1ccc(CC(N)=O)cc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1ccc(CC(N)=O)cc1)=O ITWIYDCRMLYAJX-UHFFFAOYSA-N 0.000 description 1
- PQWYVNOTKYZSSZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1ccc(CC(O)=O)cc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CC1)CCN1c1ccc(CC(O)=O)cc1)=O PQWYVNOTKYZSSZ-UHFFFAOYSA-N 0.000 description 1
- NERBLCVCQKXTEP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1CCNCC1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1CCNCC1)=O NERBLCVCQKXTEP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87490706P | 2006-12-14 | 2006-12-14 | |
| PCT/US2007/025225 WO2008076243A2 (en) | 2006-12-14 | 2007-12-10 | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513272A true JP2010513272A (ja) | 2010-04-30 |
| JP2010513272A5 JP2010513272A5 (https=) | 2010-11-18 |
Family
ID=39536880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541322A Withdrawn JP2010513272A (ja) | 2006-12-14 | 2007-12-10 | アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8399485B2 (https=) |
| EP (1) | EP2112880A4 (https=) |
| JP (1) | JP2010513272A (https=) |
| AU (1) | AU2007334519A1 (https=) |
| CA (1) | CA2672059A1 (https=) |
| WO (1) | WO2008076243A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014524898A (ja) * | 2011-06-09 | 2014-09-25 | ライゼン・ファーマシューティカルズ・エスアー | Ｇｐｒ−１１９のモジュレータとしての新規化合物 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| KR101563793B1 (ko) | 2010-10-08 | 2015-10-27 | 카딜라 핼쓰캐어 리미티드 | 신규한 ｇｐｒ 119 작용물질 |
| US20140066369A1 (en) * | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| KR20180053386A (ko) | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| EP3373933B1 (en) * | 2015-11-12 | 2020-08-26 | Merck Sharp & Dohme Corp. | Bispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| WO2018068297A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| WO2018068296A1 (en) | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242924A (en) | 1992-07-02 | 1993-09-07 | Sterling Winthrop Inc. | Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents |
| US5364865A (en) | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| AR013693A1 (es) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
| AP2001002240A0 (en) | 1999-02-08 | 2001-09-30 | Searle & Co | Sufamato hydroxamic acid metalloprotease inhibitor. |
| US6800646B1 (en) * | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
| US6498161B1 (en) * | 1999-04-06 | 2002-12-24 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| ES2316964T3 (es) | 2003-02-24 | 2009-04-16 | Arena Pharmaceuticals, Inc. | Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa. |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| RU2007107177A (ru) * | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
| GB0419160D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Ｇタンパク質結合受容体作動薬 |
| EP1838311A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
-
2007
- 2007-12-10 EP EP07862712A patent/EP2112880A4/en not_active Withdrawn
- 2007-12-10 JP JP2009541322A patent/JP2010513272A/ja not_active Withdrawn
- 2007-12-10 AU AU2007334519A patent/AU2007334519A1/en not_active Abandoned
- 2007-12-10 CA CA002672059A patent/CA2672059A1/en not_active Abandoned
- 2007-12-10 WO PCT/US2007/025225 patent/WO2008076243A2/en not_active Ceased
- 2007-12-10 US US12/517,142 patent/US8399485B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014524898A (ja) * | 2011-06-09 | 2014-09-25 | ライゼン・ファーマシューティカルズ・エスアー | Ｇｐｒ−１１９のモジュレータとしての新規化合物 |
| US9777018B2 (en) | 2011-06-09 | 2017-10-03 | Rhizen Pharmaceuticals Sa | Compounds as modulators of GPR-119 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2112880A4 (en) | 2011-12-21 |
| AU2007334519A1 (en) | 2008-06-26 |
| US8399485B2 (en) | 2013-03-19 |
| US20100075987A1 (en) | 2010-03-25 |
| WO2008076243A3 (en) | 2009-03-26 |
| WO2008076243A2 (en) | 2008-06-26 |
| EP2112880A2 (en) | 2009-11-04 |
| CA2672059A1 (en) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513272A (ja) | アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 | |
| US8445499B2 (en) | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | |
| EP2297129B1 (en) | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | |
| US9365539B2 (en) | Prolylcarboxypeptidase inhibitors | |
| JP5935154B2 (ja) | Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド | |
| JP2010533712A (ja) | 抗糖尿病化合物としてのベータカルボリン誘導体 | |
| US20130261108A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| JP2012515781A (ja) | 架橋および縮合複素環式抗糖尿病化合物 | |
| JP2012515782A (ja) | 抗糖尿病性架橋および縮合化合物 | |
| KR20090127902A (ko) | 벤즈이미다졸 유도체 및 이의 사용방법 | |
| JP2010520199A (ja) | ピペリジン誘導体およびその使用方法 | |
| KR20240118891A (ko) | 플루오로페닐 베타-히드록시에틸아민 및 과혈당증의 치료에서의 이의 용도 | |
| US20120041012A1 (en) | Substituted spirocyclic amines useful as antidiabetic compounds | |
| US8759539B2 (en) | Substituted bicyclic amines for the treatment of diabetes | |
| US8669252B2 (en) | Prolylcarboxypeptidase inhibitors | |
| US20130059830A1 (en) | Novel prolylcarboxypeptidase inhibitors | |
| WO2005105743A1 (ja) | 含窒素複素環化合物およびその医薬用途 | |
| JP2016510810A (ja) | オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 | |
| WO2014180544A1 (en) | Hydantoine derivatives as cd38 inhibitors | |
| EP2352373A1 (en) | Triazole beta carboline derivatives as antidiabetic compounds | |
| US6881736B1 (en) | Vitronectin receptor antagonists | |
| KR20140098852A (ko) | Cxcr3 수용체 길항제들로서의 사이클로알칸 카복실산 유도체들 | |
| JP2008501027A (ja) | 抗糖尿病活性をもつベンゾ尿素 | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100929 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100929 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120125 |